Alnylam Pharmaceuticals ($ALNY) received a Notice of Allowance from the U.S. Patent and Trademark Office for an application granting the company new claims to RNA interference (RNAi) medicines. The application, Tuschl '262, covers double-stranded molecules with up to 25 base pairs, and the notice of allowance means the application has survived, according to the U.S. Patent and Trademark Office website. Alnylam is a global leader in RNAi therapeutics and will continue to advance claims in the innovative treatment method, Senior Vice President Laurence Reid said in a statement. The Tuschl '262 is the latest in a family of patents held by the company detailing compositions, uses and delivery methods of RNAi therapeutics. More